Kymera Therapeutics (NASDAQ:KYMR) Now Covered by Citigroup

Citigroup started coverage on shares of Kymera Therapeutics (NASDAQ:KYMR) in a report published on Thursday, Marketbeat reports. The firm issued a buy rating and a $52.00 price target on the stock.

Several other research firms have also commented on KYMR. BMO Capital Markets started coverage on Kymera Therapeutics in a research report on Friday, December 6th. They issued a “market perform” rating and a $55.00 price objective on the stock. Leerink Partners reiterated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Friday, December 27th. HC Wainwright boosted their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $38.00 to $57.00 in a research report on Monday, December 2nd. Finally, BTIG Research started coverage on shares of Kymera Therapeutics in a research note on Tuesday, December 10th. They set a “buy” rating and a $60.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $56.36.

Kymera Therapeutics Trading Down 4.7 %

Shares of KYMR opened at $33.45 on Thursday. Kymera Therapeutics has a twelve month low of $29.07 and a twelve month high of $53.27. The firm has a market capitalization of $2.17 billion, a P/E ratio of -14.29 and a beta of 2.22. The stock’s fifty day simple moving average is $37.57 and its 200 day simple moving average is $42.95.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The firm had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. Sell-side analysts predict that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Transactions at Kymera Therapeutics

In related news, CFO Bruce N. Jacobs sold 7,035 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the sale, the chief financial officer now directly owns 201,886 shares of the company’s stock, valued at $6,147,428.70. The trade was a 3.37 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the sale, the chief operating officer now owns 67,800 shares in the company, valued at $2,064,510. The trade was a 2.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,788 shares of company stock valued at $455,202. Insiders own 15.82% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Blue Trust Inc. raised its holdings in shares of Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after purchasing an additional 270 shares during the period. State of Wyoming acquired a new stake in Kymera Therapeutics during the fourth quarter worth about $45,000. GF Fund Management CO. LTD. bought a new position in Kymera Therapeutics in the fourth quarter worth about $55,000. KBC Group NV boosted its stake in Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after acquiring an additional 752 shares during the period. Finally, Quarry LP acquired a new position in Kymera Therapeutics in the third quarter valued at approximately $95,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.